Table 2.
Descriptive characteristics of the 87 participants with acute myeloid leukaemia (AML). Data displayed as n (%) unless otherwise indicated.
| n (%) | ||
|---|---|---|
| Age | ||
| Median (IQR) | 60 (47.5–69.0) | |
| Gender | ||
| Female | 42 (48%) | |
| Male | 45 (52%) | |
| Treatment | ||
| Chemotherapy | 49 (56%) | |
| AlloSCT | 29 (33%) | |
| Surveillance | 7 (8%) | |
| Chemotherapy regimens | ||
| Intensive chemotherapy | 32 (37%) | |
| Hypomethylating agent-based | 5 (6%) | |
| Low-dose cytarabine-based regimen | 12 (14%) | |
| Conditioning regimens | ||
| Reduced-intensity conditioning | 19 (22%) | |
| Myeloablative conditioning | 10 (11%) | |
| Donor type | ||
| Matched unrelated donor | 14 (16%) | |
| Haploidentical donor | 11 (13%) | |
| Sibling donor | 4 (5%) | |
| Genetics | ||
| t(8;21) (RUNX1-RUNX1T1) | 8 (9%) | |
| inv(16) (CBFB-MYH11) | 2 (2%) | |
| NPM1 mutations | 18 (21%) | |
| t(9;22) (BCR-ABL1) | 1 (1%) | |
| ELN risk | ||
| Favourable | 25 (29%) | |
| Intermediate | 23 (26%) | |
| Adverse | 29 (33%) | |
| Other | 6 (7%) | |
| Flow MRD | ||
| Positive | 44 (51%) | |
| Negative | 23 (26%) | |
| Indeterminate | 20 (23%) | |
AlloSCT—allogeneic stem cell transplant; MRD—measurable residual disease. Note: There are missing data for treatment (n = 2) and ELN risk (n = 4).